Incycus Therapeutics Appoints Melissa Beelen as Vice President, Clinical Operations
03 avr. 2019 08h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics Announces FDA Approval of IND Application for a Novel Gamma-Delta (γδ) T Cell Therapy for Treatment of Patients With Newly-Diagnosed Glioblastoma
01 avr. 2019 08h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, April 01, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Fluidigm Introduces the First Complete Sample-to-Answer Solution for Deep Immune Profiling by Mass Cytometry
28 mars 2019 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Todos Medical to Present at Two Upcoming Investor Conferences
28 mars 2019 08h00 HE
|
Todos Medical Ltd.
REHOVOT, Israel, March 28, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection...
Todos Medical Appoints Dr. Colin Bier to Its Board of Directors
27 mars 2019 08h00 HE
|
Todos Medical Ltd.
REHOVOT, Israel, March 27, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection...
Genomics England and Cambridge Cancer Genomics (CCG.ai) announce immunotherapy partnership
20 mars 2019 20h00 HE
|
Cambridge Cancer Genomics
CAMBRIDGE, United Kingdom, March 20, 2019 (GLOBE NEWSWIRE) -- Genomics England, the Department of Health and Social Care’s genomics spin-out, and Cambridge Cancer Genomics (CCG.ai), a precision AI...
Incysus Therapeutics to Present New Data at the American Association for Cancer Research (AACR) Annual Meeting 2019
19 mars 2019 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, March 19, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Harpoon Therapeutics to Participate in Upcoming William Blair Cancer Immunotherapy Conference
13 mars 2019 16h07 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 13, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers,...
CORRECTING and REPLACING - Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001
11 mars 2019 12h54 HE
|
Sorrento Therapeutics, Inc.
SEOUL, South Korea and SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Sorrento Therapeutics, Inc. (Nasdaq: SRNE), please note that in the...
Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001
11 mars 2019 07h00 HE
|
Sorrento Therapeutics, Inc.
SEOUL, South Korea and SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- Yuhan Corporation (000100.KS; Yuhan) and Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced today that ImmuneOncia, a joint...